The Studies of Tumor Alterations Responsive to Targeting Receptor Kinases-2 (STARTRK-2) study is a global, Phase 2 multi-site basket study designed to evaluate the safety and clinical effectiveness of entrectinib (RXDX-101) as a targeted cancer therapy (ClinicalTrials.gov identifier NCT0256826).
Entrectinib is an investigational oral medication taken once a day. It was developed to target the genetic changes found in some cancer cells.
Patients can undergo testing for NTRK1, NTRK2, NTRK3, ROS1, or ALK genes  that serve as markers for targeted treatment with Entrectinib.  The form below can be used with your oncologist to test for these possible gene targets.
STARTRK-2-Doctor-Discussion-Guide
In Phase 1 trials, entrectinib achieved tumor shrinkage for people with a variety of cancers who tested positive for these mutations.  This shows promise for these patients with many different tumor types harboring these genetic abnormalities.  Offering HOPE to many who have not had  successful disease control with more conventional treatments.
